N myc interactor/NMI Antibody [B12H19]

Catalog No.: F8354

    Application: Reactivity:

    当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    使用情報

    Dilution
    1:10000-1:50000
    1:40-1:60
    1:50
    1:100
    Application
    WB, IP, IHC, IF
    Source
    Rabbit Monoclonal Antibody
    Reactivity
    Human
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW Observed MW
    35 kDa 39 kDa
    *なぜ予測分子量と実際の分子量が異なるのか?
    下記の原因により、実際の分子量が予測と異なる:タンパク質の翻訳後修飾(リン酸化/糖鎖付加),スプライシングバリアント,イソフォーム,相対的な電荷,ポリマー。

    Datasheet & SDS

    生物学的記述

    Specificity
    N myc interactor/NMI Antibody [B12H19] detects endogenous levels of total N myc interactor/NMI protein.
    Clone
    B12H19
    Synonym(s)
    N-myc-interactor, Nmi, N-myc and STAT interactor, NMI
    Background
    N‑Myc interactor (NMI) is a co-regulatory protein originally identified through its physical association with Myc family oncoproteins and STAT transcription factors and is now recognized as a cytokine‑inducible modulator of oncogenic and innate immune signaling that acts both intracellularly and, in some contexts, as a secreted damage‑associated signal. The protein lacks obvious enzymatic domains and instead contains coiled‑coil and helical regions that support hetero‑oligomeric complex formation with basic helix–loop–helix–leucine zipper transcription factors such as N‑Myc and c‑Myc and with STATs, including STAT1 and STAT5, and these interactions position NMI as a scaffold that influences transcriptional output rather than DNA‑binding specificity. NMI binds multiple STAT family members (all except STAT2) and enhances STAT‑dependent transcription in response to IL‑2 and IFN‑γ by promoting recruitment of CBP/p300 coactivators to STAT1‑ and STAT5‑containing complexes, thereby amplifying cytokine‑driven gene expression programs involved in growth control, differentiation, and immune effector function. In parallel, NMI associates with Myc proteins and with BRCA1 in a tricomplex that can repress c‑Myc‑induced hTERT promoter activity in breast cancer, and it modulates Myc‑dependent transcriptional programs that control proliferation, apoptosis, and telomerase regulation, linking NMI abundance and localization to Myc oncogenic potency. NMI also participates in Wnt/β‑catenin signaling control: enforced NMI expression upregulates the Wnt antagonist DKK1, destabilizes β‑catenin, reduces expression of β‑catenin target genes such as cyclin D1, and retards tumor cell growth, indicating that NMI can antagonize pro‑proliferative Wnt signaling and intersect with Myc‑driven networks through shared target pathways. In innate immune regulation, NMI is induced by interferons and forms a complex with IFI35 that stabilizes IFI35 and shapes type I interferon and NF‑κB outputs; ubiquitination of the NMI–IFI35 complex by TRIM21 and NMI‑dependent degradation of IRF7 attenuate virus‑triggered IFN‑β production, while secreted NMI released from injured or activated macrophages binds TLR4 on neighboring macrophages to activate NF‑κB and drive production of pro‑inflammatory cytokines, which defines NMI as both an intracellular signaling regulator and an extracellular DAMP in inflammatory microenvironments.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください